1-7 of 7
Kwee L. Yong, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1/2 Study Of KW-2478, An Hsp 90 Inhibitor, In Combination With Bortezomib (BTZ) In Patients (Pts) With Relapsed/Refractory (R/R) Multiple Myeloma (MM)

Cavanagh Jamie, MD, Honorata Giongco Baylon, MD, Priscilla B. Caguioa, MD, Faith E. Davies, MD, Mecide Gharibo, MD, Shiro Akinaga, PhD, Michael R. Kurman, MD, Barbara A. Novak, BS, Kwee L. Yong, PhD
Journal: Blood
Blood (2013) 122 (21): 1967.
https://doi.org/10.1182/blood.V122.21.1967.1967
Published: 2013
Journal Articles

Evaluation Of Bcma As a Therapeutic Target In Multiple Myeloma Using An Antibody-Drug Conjugate

Kwee L Yong, PhD, Fiona M Germaschewski, BSc, Manuel Rodriguez-Justo, PhD, Danton Bounds, BSc, Lydia Lee, MD, Patrick A Mayes, PhD, Katherine Sully, PhD, Laura M Seestaller-Wehr, MS, William E Fieles, MS, James R Tunstead, PhD, Lee McCahon, Jennifer Paterson, BSc, Gaelle Herledan, BSc, Jenny L Craigen, PhD
Journal: Blood
Blood (2013) 122 (21): 4447.
https://doi.org/10.1182/blood.V122.21.4447.4447
Published: 2013
Journal Articles

Single Centre Analysis Of Autologous Stem Cell Transplant Outcomes In Multiple Myeloma In 338 Consecutive Patients: Maintenance/Consolidation Is Associated With Superior Survival, But Early Relapse Is The Single Most Important Predictor Of Survival and May Override Genetic Risk

Paul M Maciocia, MRCP, Nicholas Counsell, Antonia Bird, Laura Percy, Sally Moore, BSc, FRPATH, FRCP, MBBS, Neil Rabin, Shirley D'Sa, MD, Manuel Rodriguez-Justo, Kwee L Yong, PhD
Journal: Blood
Blood (2013) 122 (21): 2159.
https://doi.org/10.1182/blood.V122.21.2159.2159
Published: 2013
Journal Articles

A Second Autologous Stem Cell Transplant (ASCT2) Induces Superior Durability Of Response (DuR) Following Bortezomib-Containing Re-Induction Therapy For Relapsed Multiple Myeloma (MM): Final Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

Gordon Cook, MD, PhD, Cathy D. Williams, MBBS, MCRP, FRCPath, David A Cairns, PhD, Marie Fletcher, J. D. Cavenagh, MD, MRCP, John A Snowden, MD, FRCP, FRCPath, Christopher Parrish, MD, John Ashcroft, Kwee L Yong, PhD, Jim Cavet, FRCPath, Hannah Hunter, MB, FRCPath, MRCP, Jennifer Bird, Sheila J O'Connor, Julia MB Brown, Treen Morris
Journal: Blood
Blood (2013) 122 (21): 765.
https://doi.org/10.1182/blood.V122.21.765.765
Published: 2013
Journal Articles

Identifying An Optimally Effective But Tolerable Dose Of Bendamustine In Combination With Thalidomide and Dexamethasone In Patients With Relapsed Or Refractory Multiple Myeloma

Stephen A Schey, MD, Kwee L Yong, PhD, Cathy D. Williams, MBBS, MCRP, FRCPath, Faith E Davies, MD, Gareth J Morgan, MD PhD, James D. Cavenagh, MD, Gordon Cook, MD, PhD, Mark Cook, Avie-Lee Coney, Sarah Brown, PhD, Louise M Flanagan, PhD, Walter Gregory, PhD, Jim Cavet, FRCPath
Journal: Blood
Blood (2013) 122 (21): 286.
https://doi.org/10.1182/blood.V122.21.286.286
Published: 2013
Journal Articles

Involvement of the Tis11b/Berg36 Family in the Regulation of B-CLL Surivival and Differentiation.

Maria Baou, BSc, John Murphy, PhD, Kwee L. Yong, PhD, Robert Carr, MD, Andrew P. Jewell, PhD
Journal: Blood
Blood (2006) 108 (11): 4936.
https://doi.org/10.1182/blood.V108.11.4936.4936
Published: 2006
Journal Articles

Regulation of Berg-36 Gene Expression by Survival and Apoptotic Stimuli in B-Chronic Lymphocytic Leukaemia Cells.

Andrew P. Jewell, PhD, Maria Baou, BSc, Kwee L. Yong, PhD, Robert Carr, MD, John Murphy, PhD
Journal: Blood
Blood (2004) 104 (11): 4767.
https://doi.org/10.1182/blood.V104.11.4767.4767
Published: 2004